Tolvaptan
Ended Awarded
- Contract number
- 36C25220F0290
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 12
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $10,102
Award facts
- Contract value 100% obligated
- $10,102.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
On May 7, 2020, the Department of Veterans Affairs, Veterans Integrated Service Network 12, awarded a $10,102.19 firm fixed-price delivery order to Otsuka America Pharmaceutical Inc. for Tolvaptan. This contract represents a delivery order issued under the company's larger Blanket Purchase Agreement valued at $83.3 million for Jynarque (tolvaptan), awarded by the VA's National Acquisition Center under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Tolvaptan is a specialized pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia, conditions requiring targeted pharmaceutical intervention for veteran populations. The delivery order carried no set-aside designation and was scheduled for completion by May 29, 2020, with performance taking place in Pittsburgh, Pennsylvania.
Otsuka America Pharmaceutical Inc., headquartered in Rockville, Maryland, serves as a primary supplier of specialty pharmaceuticals to the VA Healthcare system across multiple integrated service networks. The company maintains a robust federal contracting portfolio with the VA, supported by its established Federal Supply Schedule contract for pharmaceuticals valued at approximately $396 million. This delivery order exemplifies the streamlined procurement process enabled through the company's existing indefinite delivery vehicles, allowing the VA to efficiently obtain critical pharmaceutical treatments for veterans across the nation. No subcontractors were identified for this award.
Quick answers
Who was awarded contract 36C25220F0290?
36C25220F0290 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on May 7, 2020.
How much is contract 36C25220F0290 worth?
The government has obligated $10,102 on 36C25220F0290.
Is contract 36C25220F0290 an order under another contract?
Yes. 36C25220F0290 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25220F0290 competed?
The extent of competition for 36C25220F0290 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award